Loading
Life sciences · Preprint
arXiv · November 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Preprint.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Purpose: Micro-ultrasound ($μ$US) is a promising modality for prostate cancer (PCa) detection, but identifying suspicious tissue depends heavily on clinical experience. Models trained on sparse, noisy core-level pathology offer little insight into their decisions and can fail under domain shift. Clinical use needs a traceable decision process and a flag for uncertain predictions. Methods: We introduce ProtoCouncil, in which three foundation encoders (MedSAM, DINOv3 and V-JEPA 2.1) learn case-based prototypes at three anatomical levels: whole gland, needle track and gland sectors. Prototypes are projected onto real training-core regions, and label-free fusion keeps every class logit as a bias plus an exact sum of prototype similarity contributions. Encoder disagreement triggers selective prediction. Results: In five-fold patient-level cross-validation (6,588 cores, 693 patients), ProtoCouncil reaches 82.9% AUROC for clinically significant PCa (csPCa, Grade Group $\geq$3), 4.3 points above the best previously published method. In zero-shot evaluation on two external cohorts, ProtoCouncil achieves higher all-cancer and csPCa AUROC than all previous methods. Nearest same-class exemplars match test-core tumor involvement better than random same-class cases. Externally, csPCa accuracy falls from 79% when encoders agree to 27% when two oppose the fused call. Abstaining on disagreement raises balanced accuracy by 7 and 15 points, while retaining 58% and 54% of the cores. Conclusion: ProtoCouncil grounds core-level predictions in exact similarity-based evidence from real, anatomically indexed training cases, which makes its reasoning interpretable. It achieves the highest csPCa AUROC across three cohorts and identifies unreliable predictions through encoder disagreement.